Loading...
XWAR
BMX
Market cap13mUSD
Dec 05, Last price  
11.75PLN
1D
0.86%
1Q
-8.91%
Jan 2017
142.77%
IPO
48.73%
Name

BioMaxima SA

Chart & Performance

D1W1MN
XWAR:BMX chart
P/E
92.09
P/S
0.93
EPS
0.13
Div Yield, %
Shrs. gr., 5y
2.37%
Rev. gr., 5y
11.63%
Revenues
53m
+12.96%
6,669,4287,163,84610,491,70518,818,62020,965,51020,440,95521,965,26026,984,19831,574,52630,817,69230,487,87061,609,50879,088,000143,867,00046,786,00052,851,000
Net income
535k
-8.70%
610,366539,042998,9531,375,0641,320,371454,8331,454,7471,227,716805,683013,9987,949,00010,243,00028,885,000586,000535,000
CFO
-152k
L
418,323102,8851,832,45101,249,426561,0162,286,8831,439,1421,839,4002,120,2564,927,7823,972,697-132,00037,065,0001,592,000-152,000
Dividend
Jun 16, 20230.5 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.
IPO date
Jun 08, 2010
Employees
122
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT